<p>Immunovant, Inc.（納斯達克代碼：IMVT - 獲取免費報告）在週四的交易中股價下跌了 6.4%，原因是該公司公佈的季度收益低於預期。股價最低曾跌至 33.25 美元，最後交易價為 33.2950 美元。在午盤交易中，約有 1,378,728 股被交易，較日均交易量 1,611,508 股下降了 14%。該股此前收盤價為 35.56 美元。</p>
<p>該公司報告本季度每股收益（EPS）為（0.73）美元，低於分析師一致預期的（0.60）美元，差距為（0.13）美元。去年同期，該公司每股收益為（0.64）美元。</p>
<h2>Immunovant 新聞摘要</h2>
<p>以下是本週影響 Immunovant 的主要新聞：</p>
<ul>
<li>積極情緒：Immunovant 發佈了其難治性類風濕關節炎研究的第 16 周強勁結果，反應率被投資者視為具有臨牀意義，並支持該藥物的潛力。文章標題</li>
<li>積極情緒：該公司表示其皮膚性狼瘡概念驗證試驗已完全招募，成為另一個近期催化劑，預計在 2026 年下半年發佈頂線數據。文章標題</li>
<li>積極情緒：Immunovant 還強調截至季度末的現金餘額約為 9.02 億美元，這將支持持續開發並幫助資助 IMVT-1402 在格雷夫斯病中的潛在商業推出。文章標題</li>
</ul>
<h2>分析師評級變動</h2>
<p>多家股票研究分析師最近對 IMVT 股票發佈了報告。HC Wainwright 在週四的研究報告中將 Immunovant 的目標價從 35.00 美元上調至 40.00 美元，並給予該公司 “買入” 評級。美國銀行在週四的研究報告中將 Immunovant 的目標價從 32.00 美元上調至 43.00 美元，並給予該公司 “買入” 評級。Guggenheim 在 2 月 9 日的報告中將 Immunovant 的目標價從 41.00 美元上調至 44.00 美元，並給予該公司 “買入” 評級。Weiss Ratings 在 4 月 8 日的報告中重申了對 Immunovant 股票的 “賣出（d-）” 評級。最後，Sanford C. Bernstein 在 3 月 20 日的報告中開始覆蓋 Immunovant，給予 “市場表現” 評級和 28.00 美元的目標價。目前，六位分析師對該股給予 “買入” 評級，四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Immunovant 目前的共識評級為 “持有”，共識目標價為 34.44 美元。</p>
<p><strong>獲取我們對 Immunovant 的最新分析</strong></p>
<h2>Immunovant 內部交易</h2>
<p>在相關消息中，首席財務官 Tiago Girao 於 4 月 23 日（星期四）出售了 25,760 股公司的股票，交易價格為每股 29.62 美元，總價值為 763,011.20 美元。交易後，首席財務官直接持有 247,596 股公司股票，價值約為 7,333,793.52 美元。這代表其持股比例下降了 9.42%。該交易已在 SEC 的法律文件中披露，相關信息可通過此鏈接訪問。此次出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。此外，首席運營官 Melanie Gloria 於 4 月 8 日（星期三）出售了 8,722 股公司的股票，交易價格為每股 24.83 美元，總價值為 216,567.26 美元。交易完成後，首席運營官持有 245,222 股公司股票，價值為 6,088,862.26 美元。這代表其持股比例下降了 3.43%。有關此次出售的更多細節可在官方 SEC 披露中找到。此次出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。在過去的九十天裏，內部人士共出售了 78,141 股公司股票，價值為 2,115,713 美元。目前，1.80% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>對該公司的對沖基金和其他機構投資者最近調整了持股。Granahan Investment Management LLC 在第三季度將其在 Immunovant 的持股比例提高了 24.9%。Granahan Investment Management LLC 目前持有 266,221 股公司股票，價值為 4,291,000 美元，此前在上個季度增持了 53,133 股。阿伯丁集團（Aberdeen Group plc）在第三季度將其在 Immunovant 的持股比例提高了 16.2%。阿伯丁集團目前持有 981,804 股公司股票，價值為 15,827,000 美元，此前在上個季度增持了 137,099 股。阿爾卑斯全球管理（Alpine Global Management LLC）在第三季度將其在 Immunovant 的持股比例提高了 4.9%。阿爾卑斯全球管理目前持有 2,754,731 股公司股票，價值為 44,406,000 美元，此前在上個季度增持了 128,039 股。Hennion &amp; Walsh 資產管理公司在第四季度收購了 Immunovant 的新股份，價值為 1,823,000 美元。最後，高 Vista 策略（HighVista Strategies LLC）在第三季度將其在 Immunovant 的持股比例提高了 38.5%。高 Vista 策略目前持有 253,127 股公司股票，價值為 4,080,000 美元，此前在上個季度增持了 70,319 股。目前，47.08% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Immunovant 價格表現</h2>
<p>該公司的市值為 68.4 億美元，市盈率為-12.45，貝塔係數為 0.70。該公司的 50 日移動平均價格為 26.48 美元，200 日移動平均價格為 25.78 美元。</p>
<h2>Immunovant 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Immunovant Inc 是一家臨牀階段的生物製藥公司，專注於開發針對新生兒 Fc 受體（FcRn）的新型單克隆抗體療法，以治療嚴重的自身免疫疾病。通過抑制 FcRn，Immunovant 的方案旨在降低致病性免疫球蛋白 G（IgG）抗體的水平，這些抗體在重症肌無力和免疫性血小板減少症等疾病的病理中發揮着核心作用。</p>
<p>該公司的主要資產 efgartigimod 是一種工程化的 Fc 片段，能夠選擇性地結合 FcRn，加速循環 IgG 的降解。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票超過 Immunovant</li>
<li>2 只將 AI 恐懼轉化為基本面收益的軟件股票</li>
<li>代幣接管：SEC 引發市場震盪</li>
<li>Target 展現出強勁，但分析師希望看到更多</li>
<li>NVIDIA 價格回調？別指望，業務正在加速</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Immunovant 嗎？</h2>
<p>在考慮 Immunovant 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Immunovant 並不在名單上。</p>
<p>雖然 Immunovant 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMVT

<p>Immunovant 的股票（NASDAQ:IMVT）在報告季度收益不佳後下跌 6.4%，至 33.2950 美元，虧損每股 0.73 美元，低於預期 0.13 美元。儘管如此，該公司擁有 9.02 億美元的強大現金餘額，並且在臨牀試驗中有積極進展。分析師的評級不一，其中六個 “買入” 和一個 “賣出” 評級。內部交易顯示出為滿足税務義務而進行的大量股票出售</p>

<p>Immunovant, Inc. (NASDAQ:IMVT - Get Free Report)'s stock price was down 6.4% during trading on Thursday after the company announced weaker than expected quarterly earnings. The stock traded as low as $33.25 and last traded at $33.2950. Approximately 1,378,728 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 1,611,508 shares. The stock had previously closed at $35.56.</p>
<div class="lb-trans"><p>Immunovant, Inc.（納斯達克代碼：IMVT - 獲取免費報告）在週四的交易中股價下跌了 6.4%，原因是該公司公佈的季度收益低於預期。股價最低曾跌至 33.25 美元，最後交易價為 33.2950 美元。在午盤交易中，約有 1,378,728 股被交易，較日均交易量 1,611,508 股下降了 14%。該股此前收盤價為 35.56 美元。</p>
</div><p>The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.13). During the same quarter last year, the firm posted ($0.64) earnings per share.</p>
<div class="lb-trans"><p>該公司報告本季度每股收益（EPS）為（0.73）美元，低於分析師一致預期的（0.60）美元，差距為（0.13）美元。去年同期，該公司每股收益為（0.64）美元。</p>
</div><h2>Immunovant News Summary</h2>
<div class="lb-trans"><h2>Immunovant 新聞摘要</h2>
</div><p>Here are the key news stories impacting Immunovant this week:</p>
<div class="lb-trans"><p>以下是本週影響 Immunovant 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Immunovant released strong Week 16 results from its difficult-to-treat rheumatoid arthritis study, with response rates that investors viewed as clinically meaningful and supportive of the drug’s potential. Article Title</li>
<li>Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled, creating another near-term catalyst with topline data expected in the second half of 2026. Article Title</li>
<li>Positive Sentiment: Immunovant also highlighted a cash balance of about $902 million at quarter-end, which should support ongoing development and help fund a potential commercial launch of IMVT-1402 in Graves’ disease. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Immunovant 發佈了其難治性類風濕關節炎研究的第 16 周強勁結果，反應率被投資者視為具有臨牀意義，並支持該藥物的潛力。文章標題</li>
<li>積極情緒：該公司表示其皮膚性狼瘡概念驗證試驗已完全招募，成為另一個近期催化劑，預計在 2026 年下半年發佈頂線數據。文章標題</li>
<li>積極情緒：Immunovant 還強調截至季度末的現金餘額約為 9.02 億美元，這將支持持續開發並幫助資助 IMVT-1402 在格雷夫斯病中的潛在商業推出。文章標題</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities research analysts have recently issued reports on IMVT shares. HC Wainwright upped their price target on Immunovant from $35.00 to $40.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday. Bank of America upped their price target on Immunovant from $32.00 to $43.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday. Guggenheim upped their price objective on Immunovant from $41.00 to $44.00 and gave the company a &#34;buy&#34; rating in a report on Monday, February 9th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Immunovant in a report on Wednesday, April 8th. Finally, Sanford C. Bernstein began coverage on Immunovant in a report on Friday, March 20th. They issued a &#34;market perform&#34; rating and a $28.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Immunovant presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $34.44.</p>
<div class="lb-trans"><p>多家股票研究分析師最近對 IMVT 股票發佈了報告。HC Wainwright 在週四的研究報告中將 Immunovant 的目標價從 35.00 美元上調至 40.00 美元，並給予該公司 “買入” 評級。美國銀行在週四的研究報告中將 Immunovant 的目標價從 32.00 美元上調至 43.00 美元，並給予該公司 “買入” 評級。Guggenheim 在 2 月 9 日的報告中將 Immunovant 的目標價從 41.00 美元上調至 44.00 美元，並給予該公司 “買入” 評級。Weiss Ratings 在 4 月 8 日的報告中重申了對 Immunovant 股票的 “賣出（d-）” 評級。最後，Sanford C. Bernstein 在 3 月 20 日的報告中開始覆蓋 Immunovant，給予 “市場表現” 評級和 28.00 美元的目標價。目前，六位分析師對該股給予 “買入” 評級，四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Immunovant 目前的共識評級為 “持有”，共識目標價為 34.44 美元。</p>
</div><p><strong>Get Our Latest Analysis on Immunovant</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Immunovant 的最新分析</strong></p>
</div><h2>Insider Transactions at Immunovant</h2>
<div class="lb-trans"><h2>Immunovant 內部交易</h2>
</div><p>In related news, CFO Tiago Girao sold 25,760 shares of the company's stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $29.62, for a total value of $763,011.20. Following the transaction, the chief financial officer directly owned 247,596 shares in the company, valued at approximately $7,333,793.52. This represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Melanie Gloria sold 8,722 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $24.83, for a total value of $216,567.26. Following the completion of the transaction, the chief operating officer owned 245,222 shares in the company, valued at $6,088,862.26. This represents a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 78,141 shares of company stock valued at $2,115,713 in the last ninety days. 1.80% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Tiago Girao 於 4 月 23 日（星期四）出售了 25,760 股公司的股票，交易價格為每股 29.62 美元，總價值為 763,011.20 美元。交易後，首席財務官直接持有 247,596 股公司股票，價值約為 7,333,793.52 美元。這代表其持股比例下降了 9.42%。該交易已在 SEC 的法律文件中披露，相關信息可通過此鏈接訪問。此次出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。此外，首席運營官 Melanie Gloria 於 4 月 8 日（星期三）出售了 8,722 股公司的股票，交易價格為每股 24.83 美元，總價值為 216,567.26 美元。交易完成後，首席運營官持有 245,222 股公司股票，價值為 6,088,862.26 美元。這代表其持股比例下降了 3.43%。有關此次出售的更多細節可在官方 SEC 披露中找到。此次出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。在過去的九十天裏，內部人士共出售了 78,141 股公司股票，價值為 2,115,713 美元。目前，1.80% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. Granahan Investment Management LLC raised its stake in shares of Immunovant by 24.9% in the third quarter. Granahan Investment Management LLC now owns 266,221 shares of the company's stock valued at $4,291,000 after acquiring an additional 53,133 shares in the last quarter. Aberdeen Group plc raised its stake in shares of Immunovant by 16.2% in the third quarter. Aberdeen Group plc now owns 981,804 shares of the company's stock valued at $15,827,000 after acquiring an additional 137,099 shares in the last quarter. Alpine Global Management LLC raised its stake in shares of Immunovant by 4.9% in the third quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company's stock valued at $44,406,000 after acquiring an additional 128,039 shares in the last quarter. Hennion &amp; Walsh Asset Management Inc. acquired a new stake in shares of Immunovant in the fourth quarter valued at $1,823,000. Finally, HighVista Strategies LLC raised its stake in shares of Immunovant by 38.5% in the third quarter. HighVista Strategies LLC now owns 253,127 shares of the company's stock valued at $4,080,000 after acquiring an additional 70,319 shares in the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對該公司的對沖基金和其他機構投資者最近調整了持股。Granahan Investment Management LLC 在第三季度將其在 Immunovant 的持股比例提高了 24.9%。Granahan Investment Management LLC 目前持有 266,221 股公司股票，價值為 4,291,000 美元，此前在上個季度增持了 53,133 股。阿伯丁集團（Aberdeen Group plc）在第三季度將其在 Immunovant 的持股比例提高了 16.2%。阿伯丁集團目前持有 981,804 股公司股票，價值為 15,827,000 美元，此前在上個季度增持了 137,099 股。阿爾卑斯全球管理（Alpine Global Management LLC）在第三季度將其在 Immunovant 的持股比例提高了 4.9%。阿爾卑斯全球管理目前持有 2,754,731 股公司股票，價值為 44,406,000 美元，此前在上個季度增持了 128,039 股。Hennion &amp; Walsh 資產管理公司在第四季度收購了 Immunovant 的新股份，價值為 1,823,000 美元。最後，高 Vista 策略（HighVista Strategies LLC）在第三季度將其在 Immunovant 的持股比例提高了 38.5%。高 Vista 策略目前持有 253,127 股公司股票，價值為 4,080,000 美元，此前在上個季度增持了 70,319 股。目前，47.08% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Immunovant Price Performance</h2>
<div class="lb-trans"><h2>Immunovant 價格表現</h2>
</div><p>The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of -12.45 and a beta of 0.70. The firm has a 50 day moving average price of $26.48 and a 200-day moving average price of $25.78.</p>
<div class="lb-trans"><p>該公司的市值為 68.4 億美元，市盈率為-12.45，貝塔係數為 0.70。該公司的 50 日移動平均價格為 26.48 美元，200 日移動平均價格為 25.78 美元。</p>
</div><h2>Immunovant Company Profile</h2>
<div class="lb-trans"><h2>Immunovant 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.</p>
<div class="lb-trans"><p>Immunovant Inc 是一家臨牀階段的生物製藥公司，專注於開發針對新生兒 Fc 受體（FcRn）的新型單克隆抗體療法，以治療嚴重的自身免疫疾病。通過抑制 FcRn，Immunovant 的方案旨在降低致病性免疫球蛋白 G（IgG）抗體的水平，這些抗體在重症肌無力和免疫性血小板減少症等疾病的病理中發揮着核心作用。</p>
</div><p>The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.</p>
<div class="lb-trans"><p>該公司的主要資產 efgartigimod 是一種工程化的 Fc 片段，能夠選擇性地結合 FcRn，加速循環 IgG 的降解。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Immunovant</li>
<li>2 Software Stocks Turning AI Fears Into Fundamental Gains</li>
<li>The Token Takeover: SEC Triggers Market Quake</li>
<li>Target Shows Strengths, But Analysts Want to See More</li>
<li>NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Immunovant</li>
<li>2 只將 AI 恐懼轉化為基本面收益的軟件股票</li>
<li>代幣接管：SEC 引發市場震盪</li>
<li>Target 展現出強勁，但分析師希望看到更多</li>
<li>NVIDIA 價格回調？別指望，業務正在加速</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunovant Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Immunovant 嗎？</h2>
</div><p>Before you consider Immunovant, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Immunovant 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Immunovant 並不在名單上。</p>
</div><p>While Immunovant currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immunovant 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immunovant（納斯達克股票代碼：IMVT）因收益令人失望，股價下跌 6.4%